IP Library Granted Patent US 11,077,192
Granted Patent B2
US 11,077,192 · App. 16/438,702 · Granted Aug 3, 2021

Methods for photodynamic therapy

Inventors: Scott Lundahl (Lexington, MA); Michael Guttadauro (Carlisle, MA)
Assignee: DUSA PHARMACEUTICALS, INC.
A61K41/0061A61K9/0014A61K9/08A61K31/75A61K47/10A61N5/062A61P17/12A61N2005/0633A61N2005/0642A61N2005/0652A61N2005/0659A61N2005/0663
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,077,192
App. No.
16/438,702
Granted
Aug 3, 2021
Kind
B2
Abstract

A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

Claims (23)

1. A method of photodynamic treatment of actinic keratosis, comprising:

applying 5-aminolevulinic acid (ALA) in gel form to an actinic keratotic lesion on the stratum corneum of an upper extremity; and

reducing evaporation from a portion of the stratum corneum including an area where the lesion is present using an occlusive dressing,

wherein reducing evaporation comprises applying the occlusive dressing to the area and keeping the occlusive dressing on the area at a temperature between about 19° C. to about 22° C.

2. The method of claim 1 , wherein reducing evaporation comprises applying a low density polyethylene wrap as the occlusive dressing and holding the low density polyethylene wrap in place with an elastic net.

3. The method of claim 1 , wherein reducing evaporation comprises applying the occlusive dressing to the area, and securing the occlusive dressing by a tubular elastic stretch netting.

4. The method of claim 1 , further comprising illuminating the lesion with a dose of light of 37 J/cm 2 .

5. The method of claim 1 , further comprising covering the occlusive dressing with material.

6. The method of claim 5 , wherein covering the occlusive dressing with material comprises placing the material over and around the occlusive dressing.

7. A method of photodynamic treatment of actinic keratosis, comprising:

applying 5-aminolevulinic acid (ALA) in gel form to an actinic keratotic lesion on the stratum corneum of an upper extremity; and

reducing evaporation from a portion of the stratum corneum including an area where the lesion is present using an occlusive dressing,

wherein reducing evaporation further comprises keeping the occlusive dressing on the area at a temperature between about 19° C. to about 22° C.

8. The method of claim 7 , wherein reducing evaporation comprises applying a low density polyethylene wrap as the occlusive dressing and holding the low density polyethylene wrap in place with an elastic net.

9. The method of claim 7 , wherein reducing evaporation comprises applying the occlusive dressing to the area, and securing the occlusive dressing by a tubular elastic stretch netting.

10. The method of claim 7 , further comprising illuminating the lesion with a dose of light of 37 J/cm 2 .

11. The method of claim 7 , further comprising covering the occlusive dressing with material.

12. The method of claim 11 , wherein covering the occlusive dressing with material comprises placing the material over and around the occlusive dressing.

13. A method of photodynamic treatment of actinic keratosis, comprising:

applying a topical composition of 5-aminolevulinic acid (ALA) hydrochloride at a concentration of 20% by weight to an actinic keratotic lesion on the stratum corneum of an upper extremity; and

reducing evaporation from a portion of the stratum corneum including an area where the lesion is present using an occlusive dressing,

wherein reducing evaporation comprises applying the occlusive dressing to the area and keeping the occlusive dressing on the area at a temperature between about 19° C. to about 22° C.

14. The method of claim 13 , further comprising covering the occlusive dressing with material.

Assignments (2)
MERGER Recorded May 30, 2024
From: DUSA PHARMACEUTICALS, INC.
To: SUN PHARMACEUTICAL INDUSTRIES, INC.
Reel/Frame 067565/0986 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2021
From: LUNDAHL, SCOTT; GUTTADAURO, MICHAEL
To: DUSA PHARMACEUTICALS, INC.
Reel/Frame 055717/0367 →
Continuity (2)
Continuation 15869164 · Jan 12, 2018
Related Publication 20190290763A1 · Sep 26, 2019
Cited By (1)
US 12,296,011